Engineered immune cells take on Hard-to-Treat lymphoma
Disease control
Recruiting now
This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC